American Association for Cancer Research
00085472can122460-sup-fig1.pdf (110.59 kB)

Supplementary Figure 1 from Proliferation-Independent Control of Tumor Glycolysis by PDGFR-Mediated AKT Activation

Download (110.59 kB)
journal contribution
posted on 2023-03-30, 22:04 authored by Cong Ran, Huan Liu, Yasuyuki Hitoshi, Mark A. Israel

PDF file - 110K, Figure S1. Doxycyline inhibits growth but not survival in dox-sensitive TSC cultures.



The differences in glucose metabolism that distinguish most malignant and normal tissues have called attention to the importance of understanding the molecular mechanisms by which tumor energy metabolism is regulated. Receptor tyrosine kinase (RTK) pathways that are implicated in proliferation and transformation have been linked to several aspects of tumor glucose metabolism. However, the regulation of glycolysis has invariably been examined under conditions in which proliferation is concomitantly altered. To determine whether RTKs directly regulate glycolysis without prerequisite growth modulation, we first identified a specific RTK signaling pathway, platelet-derived growth factor (PDGF)/PDGF receptor (PDGFR) that regulates glycolysis in glioma-derived tumor stem-like cells from a novel mouse model. We determined that PDGF-regulated glycolysis occurs independent of PDGF-regulated proliferation but requires the activation of AKT, a known metabolic regulator in tumor. Our findings identifying a key characteristic of brain tumors, aerobic glycolysis, mediated by a pathway with multiple therapeutic targets suggests the possibility of inhibiting tumor energy metabolism while also treating with agents that target other pathways of pathologic significance. Cancer Res; 73(6); 1831–43. ©2013 AACR.